Iambic hands its cancer-pill gamble to Nasdaq after $461.8M of private money
The Nvidia-backed AI drug-discovery company filed to list as IAM carrying a $77.3 million annual loss against $9.4 million of partnership revenue. The private holders get their public mark; public buyers fund the trials.
Vincent Jiangthree-minute read
The blanks are the pricing fight
On Monday, 21 September 2026, Iambic Therapeutics filed its S-1 to list on Nasdaq as IAM, with J.P. Morgan, Jefferies, BofA Securities and Citigroup running the book 12. The share count and the price range are blank, and those blanks are where the two camps meet 1. Incorporated in 2019 as Entos, the San Diego company sells what it calls molecular superintelligence: AI models that design molecules, robotic labs that synthesize and test hundreds of compounds per program each week 2.
What the fresh cash buys
Renaissance Capital frames the raise at up to $100 million 3. Net proceeds plus existing cash go to three wholly owned cancer programs: IAM1363, an oral, brain-penetrant HER2 inhibitor in a Phase 1/1b trial with a registrational study possible as early as 2027, and IAM217 and IAM-C1, two preclinical candidates with US IND filings expected this quarter 2.
The ledger riding along
In 2025 Iambic booked $9.4 million of revenue against a $77.3 million net loss, after $1.2 million and $47.9 million in 2024 12. Trailing revenue reached $18 million through 30 June 2026 3. Every dollar so far is partnership money, not drug sales, and the S-1 concedes the platform has not yet led to an approved drug product 2.
The hole grew faster than the top line: Iambic's net loss outran revenue in both years
- Revenue
- Net loss
Data
| Revenue | Net loss | |
|---|---|---|
| 2024 | $1.2M | -$47.9M |
| 2025 | $9.4M | -$77.3M |
Who gets the public mark
Private investors put in about $461.8 million through 18 September 2026; the holders above 5 percent are Catalio, Nexus Ventures, Q Healthcare Holding, Nvidia−2.32% — Nvidia, down 2.32 percent today and Coatue 2. Employees hold options on 17.2 million shares at a $1.31 weighted-average strike, and the filing states that prior investors bought at prices lower than the coming public price 2. One stated purpose of the offering is to "create a public market" and ease later sales by stockholders and employees 2.
The pharma hedge, and a window that keeps clearing
The hedge is in the payment terms. AbbVie, which announced its collaboration the same morning, pays an upfront and then success-based milestones and tiered royalties 4; Takeda's February 2026 deal carries success-based payments potentially above $1.7 billion, plus royalties 5. The partners pay when programs succeed, while IPO buyers hold the equity straight through failure. Jazz, Bayer, Lundbeck and Revolution Medicines sit on the same partner list 2.
Why does the 2026 window keep clearing filings whose losses run near eight times revenue? Because biotech is where the returns are: all five of this year's best-performing IPOs above $50 million are biotechs, with a wave of drugmaker acquisitions underwriting demand, in Renaissance strategist Matt Kennedy's count 6. The free pass may be narrowing anyway; Electra Therapeutics raised $350 million in an upsized IPO on Friday and closed down 11.7 percent, and Kennedy expects the sector to draw more scrutiny from here 7.
Second Nvidia-backed S-1 in three days
Nscale, the month's other Nvidia-backed filer, posted a $1.02 billion first-half loss on $140.6 million of revenue while chasing a reported $30 billion valuation 8, a cap table The Inference unpacked on Monday. Nvidia holds more than 5 percent of Iambic and appears in its partner roster alongside AbbVie and Takeda 2; whether that seat moves the eventual price is the one question the coming amendment will not answer. Watch the amendment that fills in the range, then the fourth-quarter INDs. The private money built the platform. The public money buys the trials.
Get Deals by email, free
The acquisitions, rounds and contracts that move AI money. In our daily email, every weekday.
More about NVIDIA
NVDAFiscal Q2 2027Revenue rose 106% to $96.2B, 92.5% of it from Data Center, “driven by the ramp of our Blackwell Ultra infrastructure”. Gains on equity stakes of $7.8B lifted net income to $59.7B.
Show as a table
| Line | Value |
|---|---|
| Revenue | $96.2B |
| Gross margin | 75.0% |
| Operating margin | 66.2% |
| Net income | $59.7B |
| Hyperscale | $48.7B |
| AI clouds & enterprise | $40.3B |
| Data Center | $89.0B |
| Edge Computing | $7.2B |
| Gross profit | $72.1B |
| Cost of revenue | $24.1B |
| Other income | $7.8B |
| Operating income | $63.7B |
| Operating expenses | $8.4B |
| Tax | $11.8B |
| R&D | $7.1B |
| SG&A | $1.4B |







Reader comments
0 comments